Previous 10 | Next 10 |
LONDON, UK / ACCESSWRE / December 19, 2022 / Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR inhibitor) in solid tumors. The col...
KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING PR Newswire SYDNEY , Dec. 15, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development c...
Kazia Therapeutics ( NASDAQ: KZIA ) received Nasdaq deficiency notification , notifying the company that it is not in compliance with the minimum bid price requirement. Based on the closing bid price of Kazia's American Depository Shares, each representing ten ordinary shares of t...
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION PR Newswire SYDNEY , Dec. 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market L...
COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL PR Newswire SYDNEY , Dec. 1, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to an...
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING PR Newswire SYDNEY , Nov. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug developme...
Kazia Therapeutics ( NASDAQ: KZIA ) stock rose ~2% on Wednesday after the company provided update on Q1'23 cash flow report and said that it has sufficient cash to last till end of CY22. Kazia added that with multiple studies expected to read-out in CY23, the next fe...
LONDON, UK / ACCESSWIRE / November 2, 2022 / Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadblock (failing to graduate to stage two of the GBM AGILE ...
Kazia Therapeutics ( NASDAQ: KZIA ) gained ~31% pre-market Thursday after the oncology-focused biotech announced that its lead candidate, paxalisib demonstrated anti-tumor activity in multiple preclinical models with the metastatic form of skin cancer melanoma. The res...
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA PR Newswire SYDNEY , Oct. 27, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
Kazia Therapeutics Limited Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...